Literature DB >> 16193100

Control of cancers by combining antiangiogenesis and cancer immunotherapy.

Michelle Moniz1, Jessica Yeatermeyer, T-C Wu.   

Abstract

Ideally, cancer therapy would eliminate tumor growth at multiple sites in the body without damaging normal cells. In this regard, antiangiogenesis and immunotherapy may represent two potential approaches for control of cancers. Inhibition of tumor-specific angiogenesis restrains neoplastic growth by sequestering cancerous cells from an adequate blood supply, while activation of cancer-specific T cell-mediated immune responses can initiate attacks on tumors associated with a specific antigen. A novel approach that combines both strategies may potentially generate a better antitumor effect. In this review, we will outline the fields of cancer antiangiogenesis and cancer immunotherapy, including their advantages and limitations. In addition, we will discuss the feasibility of combining both mechanisms to generate a more powerful strategy for cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16193100     DOI: 10.1358/dot.2005.41.7.893623

Source DB:  PubMed          Journal:  Drugs Today (Barc)        ISSN: 1699-3993            Impact factor:   2.245


  4 in total

1.  Treatment with mANT2 shRNA enhances antitumor therapeutic effects induced by MUC1 DNA vaccination.

Authors:  Yun Choi; Yong H Jeon; Ji-Young Jang; June-Key Chung; Chul-Woo Kim
Journal:  Mol Ther       Date:  2010-11-09       Impact factor: 11.454

2.  Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination.

Authors:  Tae Heung Kang; Jin Hyup Lee; Chung Kil Song; Hee Dong Han; Byung Cheol Shin; Sara I Pai; Chien-Fu Hung; Cornelia Trimble; Jong-Seok Lim; Tae Woo Kim; T-C Wu
Journal:  Cancer Res       Date:  2007-01-15       Impact factor: 12.701

3.  Immune effects of bevacizumab: killing two birds with one stone.

Authors:  Yasir Y Elamin; Shereen Rafee; Sinead Toomey; Bryan T Hennessy
Journal:  Cancer Microenviron       Date:  2014-10-18

4.  The radiosensitization effects of Endostar on human lung squamous cancer cells H-520.

Authors:  Zhen Y You; Yong Zhao; Feng Liu; Ying D Zhang; Jun J Wang
Journal:  Cancer Cell Int       Date:  2010-05-24       Impact factor: 5.722

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.